The role of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis
Author:
Deban Mélina12, Châtelain Julien1, Fasquelle François3, Clerc Daniel1ORCID, Toussaint Laura1, Hübner Martin1, Teixeira Farinha Hugo1
Affiliation:
1. Department of Visceral Surgery , Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV) , Lausanne , Switzerland 2. Section of Surgical Oncology, Department of Surgery , University of Calgary , Calgary , Canada 3. Faculty of Biology and Medicine UNIL , Institute of pathology, Lausanne University Hospital (CHUV) , Lausanne , Switzerland
Abstract
Abstract
Objectives
Cytology of ascites or peritoneal washing is a routine part of staging of peritoneal metastases (PM). We aim to determine value of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Methods
Single-center retrospective cohort study included consecutive patients having PIPAC for PM of different primary between January 2015 and January 2020.
Results
A total of 75 patients (median 63 years (IQR 51–70), 67 % female) underwent a total of 144 PIPAC. At PIPAC 1 59 % patients had positive and 41 % patients had negative cytology. Patients with negative and positive cytology only differed in terms of symptoms of ascites (16% vs. 39 % respectively, p=0.04), median ascites volume (100 vs. 0 mL, p=0.01) and median PCI (9 vs. 19, p<0.01). Among 20 patients who completed 3 PIPACs (per protocol), cytology changed in one from positive to negative, and in two from negative to positive. Median overall survival was 30.9 months in the per protocol group and 12.9 months in patients having <3 PIPACs (=0.519).
Conclusions
Positive cytology under PIPAC treatment is more frequently encountered in patients with higher PCI and symptomatic ascites. Cytoversion was rarely observed and cytology status had no impact on treatment decisions in this cohort.
Publisher
Walter de Gruyter GmbH
Reference22 articles.
1. Cortes-Guiral, D, Hubner, M, Alyami, M, Bhatt, A, Ceelen, W, Glehen, O, et al.. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Prim 2021;7:91. https://doi.org/10.1038/s41572-021-00326-6. 2. Alyami, M, Hubner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368–77. https://doi.org/10.1016/S1470-2045(19)30318-3. 3. Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, Hubner, M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669–78. https://doi.org/10.1002/bjs.10521. 4. Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura Peritoneum 2016;1:99–107. https://doi.org/10.1515/pp-2016-0011. 5. Benzerdjeb, N, Durieux, E, Tantot, J, Isaac, S, Fontaine, J, Harou, O, et al.. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology 2020;77:548–59. https://doi.org/10.1111/his.14092.
|
|